Početna › Skleroderma › North Carolina
Kliničke studije za Skleroderma u državi North Carolina
9 studija za Skleroderma traži sudionike na lokacijama u državi North Carolina.
Gradovi u državi North Carolina
Službeni tekst studije (engleski)
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
U tijeku regrutacijaFaza 1
Od 18 do 74 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT07085104A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- University of North Carolina TraCS Institute - CTRC, Chapel Hill
U tijeku regrutacijaFaza 1
Od 18 do 70 godina · Oba spola · Ažurirano 28. kol 2026. · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Duke University Medical Center, Durham
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Duke University, Durham
U tijeku regrutacijaFaza 2/3
Od 18 do 75 godina · Oba spola · Ažurirano 17. kol 2026. · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Charlotte
U tijeku regrutacijaFaza 1/2
Od 18 do 75 godina · Oba spola · Ažurirano 7. kol 2026. · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Statesville, Statesville
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chapel Hill
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 28. srp 2026. · NCT07295847A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 14. srp 2026. · NCT07115745A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
U tijeku regrutacijaFaza 1
Od 12 do 70 godina · Oba spola · Ažurirano 22. svi 2026. · NCT06308978Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.